MicroPET Program Expanded with Addition of Siemens Inveon Imaging System
March 29, 2010 – As part of our ongoing commitment to offering a broad suite of validated state-of-the-art imaging technologies in models of disease, we have added a Siemens Inveon small animal PET scanner to our Discovery and Imaging Services portfolio.
The new system will facilitate the expansion of our PET imaging programs in the areas of oncology, inflammation, cardiovascular and metabolic disease. It will also increase PET imaging efficiency and capacity, allowing more rapid generation of clinically relevant image-based end points and minimizing study timelines for clients.
The Inveon represents a new class of preclinical multimodality imaging solutions, offering a comprehensive range of imaging capabilities through hardware and software innovation. The Inveon platform also allows for the integration of microCT and microSPECT. For the Inveon, Siemens has developed key targeted research applications, including drug discovery, oncology, cardiology and bone research.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We can now analyze immunohistochemical biomarkers using a confocal microscope by having multiple images taken at relatively high magnification, thus allowing us the ability to construct an image of the brain section in good resolution.
Our newly validated ELISpot and FluoroSpot reader services are some of the most sensitive cellular assays available. With this technology, we now offer an even wider range of services to meet vaccine development needs.
Jun 24–Jun 26
Charles River is once again delighted to be supporting Skin Forum. Our expert scientists will be attending the Annual Meeting and will be happy to meet with you to discuss your dermal product requirements and help you determine how our global capabilities can benefit your development program.
Jun 21–Jun 25
This five-day meeting draws diverse professionals from around the world to share their breakthroughs in the prevention, diagnosis and treatment of diabetes.
Sep 09–Sep 11
This year's "Biotechnology-Derived Therapeutics: Perspectives on Nonclinical Development" Symposium will be held on September 9-11 at the Hilton Carlsbad Oceanfront Resort and Spa in Carlsbad, CA. This Charles River sponsored event unites drug development professionals in an interactive setting to discuss the nonclinical development of biologics, including regulatory issues and innovative approaches to problem-solving.
Jun 28–Jun 28
Charles River offers a wide range of seminars, workshops and training courses for animal technicians, veterinarians, biologists and laboratory technicians who work with laboratory animals. For more information about our course on animal health monitoring, click "view more" below.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.